274 related articles for article (PubMed ID: 30478448)
1. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
3. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F; Yau C; Dobocan MC; Culjkovic-Kraljacic B; Retrouvey H; Puckett R; Flores LM; Krop IE; Rousseau C; Cocolakis E; Borden KL; Benz CC; Miller WH
Clin Cancer Res; 2011 May; 17(9):2874-84. PubMed ID: 21415224
[TBL] [Abstract][Full Text] [Related]
6. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.
Borden KL
Clin Invest Med; 2011 Dec; 34(6):E315. PubMed ID: 22129918
[TBL] [Abstract][Full Text] [Related]
7. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
8. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
9. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
11. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis A; Topisirovic I; Culjkovic B; Shao L; Borden KL
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18105-10. PubMed ID: 15601771
[TBL] [Abstract][Full Text] [Related]
12. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ; Borden KL
Immunol Rev; 2015 Jan; 263(1):210-23. PubMed ID: 25510279
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis.
Tan H; He L; Cheng Z
Biochem Biophys Res Commun; 2020 Aug; 529(3):519-525. PubMed ID: 32736668
[TBL] [Abstract][Full Text] [Related]
15. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
16. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
[TBL] [Abstract][Full Text] [Related]
17. Amlexanox Downregulates S100A6 to Sensitize
Tamai H; Yamaguchi H; Miyake K; Takatori M; Kitano T; Yamanaka S; Yui S; Fukunaga K; Nakayama K; Inokuchi K
Cancer Res; 2017 Aug; 77(16):4426-4433. PubMed ID: 28646023
[TBL] [Abstract][Full Text] [Related]
18. Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation.
Hu Z; Zhen L; Li Q; Han Q; Hua Q
Biochem Biophys Res Commun; 2019 Jun; 513(4):862-868. PubMed ID: 31000196
[TBL] [Abstract][Full Text] [Related]
19. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
